Everolimus (EVL), a specific oral mTOR inhibitor, has been approved by the U.S. Food and Drug Administration to treat various cancers, such as breast cancer, pancreatic cancer and renal cell carcinoma32. The gene discussed is MTOR; the disease is cancer.